Last week, Regeneron Pharmaceuticals announced plans to purchase genetic testing company 23andMe for $256 million through a bankruptcy auction, in today's bite-sized hospital and health industry news from Maryland, New York, and Washington.
Operating margins at many health systems have improved in the past couple of years. But not only is there still a long way to go, today's political and economic climate is further destabilizing health system finances. In this session, experts from Optum Advisory will discuss strategies for improving financial outcomes; unlocking new sources of revenue growth; and decreasing operational, clinical, and administrative costs.
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Never miss out on the latest innovative health care content tailored to you.
This is for members only. Learn more.
Never miss out on the latest innovative health care content tailored to you.